This month, the Government opened the call for volunteers to investigate the Argentine vaccination against Covid-19, “ARVAC-Cecilia Grierson”, in its stages II and III: as reported through the Minister of ScienceArray Technology and Innovation, Daniel Filmus.
As the progression levels of national studies have been approved through the National Administration of Drugs, Food and Medical Technology (ANMAT) in accordance with the principles of this year to adhere more quickly, it is open to how to summarize a new, broader medical level.
In this new national trial of the vaccine against SARS-CoV-2, the progression of CONICET will be tested in collaboration with the National University of San Martín (UNSaM) and the Pablo Cassará laboratory with a total of 1,800 people.
The news was known this month at a press conference through Filmus and the head of the Arvac assignment, CONICET and UNSaM researcher Juliana Cassataro, who reported that the first level is in stages II and III of progression and completion.
During this initial period, the subject was tested on another 80 people for phase I and 260 for phase II and, now, in the second stage, vaccination has been implemented for 1,782 volunteers. Cassataro assured that no serious negative effects will occur in the initial controls.
“This is the first time in Argentina that we have reached this point regarding a vaccine, especially after being a superadolescent with phase 1,” Filmus wrote.
The approval of ARVAC will be essential only for Argentina, but also for different Latin American countries, to continue their vaccination campaigns against SARS-CoV-2 with specially developed aid to combat the variants of the virus circulating in the region.
“Ésta será una vacuna de refuerzo que servirá para ahorrar la importación de vacunas de otros países”, destacó Filmus al respecto. Y agregó: “Nuestra expectativa también es que ésta sea una vacuna regional, estamos trabajando para exportarla junto con los ministerios de Salud de otros países”.
Bivalent vaccination in Argentina begins trials II and III: promises to stop Ómicron and wants to launch it this year
The second level of the Phase II and III trial will be completed within a month and in the medium term when the necessary 1,782 volunteers are given the final touch. The programs are carried out in 10 separate medical centers in 4 provinces and the city of Buenos Aires (CABA).
The ARVAC-Cecilia Grierson progression team was able to briefly provide the effects of this trial to ANMAT: “We are preparing so that if we manage to gather all the volunteers in June we can have the supply,” explained Array Cassataro.
As a matter of fact about the national serum official, “to compare the effects of efficacy and safety, it will be presented to the ANMAT to seek its approval as a backup vacuum. “
La convocatoria para presentarse como voluntario para recibir la vacuna contra el Covid-19 del CONICET, la UNSaM y el Laboratorio Cassará ya está abierta online y para anotarse tan solo hay que rellenar un simple formulario.
A diferencia de la primera etapa de prueba de ARVAC, ahora podrán anotarse también los individuos con comorbilidades. Esto siempre y cuando no tengan una alta deficiencia en su respuesta inmune.
To voluntarily register, you will exactly locate the form on the official website, which will be at Participation in the development of Los Angeles’ first Argentine vaccine against COVID19 (google. com), with the following data:
In the event of pre-selection, ARVAC will contact others by email or telephone to continue with the process.
ARVAC-Cecilia Grierson is executing its maximum protection and ability to temporarily adapt to circulating strains of SARS-CoV-2. Furthermore, the initial effects of his immune reaction are “promising effects”, shown through science and the generational map.
The other strong point of the national force against Covid-19 is bivalent. It is also protected against the original SARS-CoV-2 virus, as well as against various variants of the Ómicron variant, with an almost total presence in the news worldwide.
Currently, Argentine vaccination has been expanded by registering an increase of approximately 30 times in neutralizing antibodies against this virus and Gamma.